SCHEMBL20148097

SCHEMBL20148097

CCOC(=O)C1(CO)CCN(C)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 8/20 0.51
SLC22A1 O15245 1/20 0.51
SLC6A4 P31645 1/20 0.51
ADRA1A P35348 1/20 0.51
OPRD1 P41143 1/20 0.51
OPRK1 P41145 1/20 0.51
KCNH2 Q12809 1/20 0.51
LMNA P02545 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPK1 P28482 1/20 0.41
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12950188 0.87 OPRM1 (0.53) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL164041 0.85 ALDH1A1 (0.40) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL10567693 0.83 OPRM1 (0.49) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL19325498 0.81 OPRM1 (0.48) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL379072 0.81 OPRM1 (0.48) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL20069686 0.81 L3MBTL1 (0.44) LMNAMEN1KMT2AMAPK1POLB
SCHEMBL1691128 0.81 SMN1; SMN2 (0.42) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL1691141 0.81 CYP4F2 (0.41) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL19325450 0.80 OPRM1 (0.47) OPRM1SLC22A1SLC6A4ADRA1AOPRD1
SCHEMBL22857099 0.80 LMNA (0.40) LMNAMEN1KMT2AMAPK1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 OPRM1 3497/4885SLC22A1 3801/4885SLC6A4 3586/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 OPRM1 3497/4885SLC22A1 3801/4885SLC6A4 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.